



Advances in the Management of CAD/PAD: A new treatment for thrombotic risk reduction

Please Join Us for an Innovation Stage Presentation at ACC.19

Saturday, March 16, 2019

Ernest N. Morial Convention Center

Innovation Stage - Booth #2519
New Orleans, Louisiana

10:45 AM – 11:15 AM

**Matthew Charles Becker, MD,
FACC, FSCAI, FSVM**

12:30 PM – 1:00 PM

William J. French, MD

1:30 PM – 2:00 PM

Marc Cohen, MD, FACC

PROGRAM DESCRIPTION

Patients with chronic coronary artery disease (CAD) or peripheral artery disease (PAD) are at risk for major cardiovascular events, including cardiovascular death, myocardial infarction, and stroke. Join us for a presentation describing a newly approved approach to reducing the risk of these events.

Supported by Janssen Pharmaceuticals, Inc.

PLEASE JOIN US

Seating available on a first-come, first-served basis.



Advances in the Management of CAD/PAD: A new treatment for thrombotic risk reduction

In adherence with PhRMA guidelines, spouses or other guests are not permitted to attend company-sponsored programs.

For all attendees, please be advised that information such as your name and the value and purpose of any educational item, meal, or other items of value you receive may be publicly disclosed. If you are licensed in any state or other jurisdiction, or are an employee or contractor of any organization or governmental entity, that limits or prohibits meals from pharmaceutical companies, please identify yourself so that you (and we) are able to comply with such requirements.

Please note that the company prohibits the offering of gifts, gratuities, or meals to federal government employees/officials. Thank you for your cooperation.

This promotional educational activity is not accredited. The program content is developed by Janssen Pharmaceuticals, Inc. Speakers present on behalf of the company and are required to present information in compliance with FDA requirements for communications about its medicines.

The personal information you provide may be used to contact you about your request to attend the Janssen Pharmaceuticals, Inc., educational program using your preferred method of communication as indicated by you. This information may be shared with Janssen Pharmaceuticals, Inc., its affiliates, and a third party for the sole purpose of completing your registration for this program and as required by law.

This event is not part of ACC.19, as planned by its Program Committee, and does not qualify for continuing medical education (CME), continuing nursing education (CNE) or continuing education (CE) credit.

Supported by Janssen Pharmaceuticals, Inc.